NAS10030,479+0.03%S&P7,704−0.02%GOLD$4,345+1.08%BTC$84,798+0.50%VIX15.35−2.04%live tape · as of 11:04 UTC
The Screen · Healthcare · Diagnostics & Research
Danaher Corporation
DHR · a US exchange · USD · Market cap $152.8B · 58,000 employees
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price215.84 USD
Fair value217.25
Ethical score88.2/100
RatingOVERVALUED
Our investment reviews on this name
2026-08-22Read Markup215.910.0% to today
2026-07-02Read Markdown184.30+17.1% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Danaher Corporation holds its Accumulation at $215.84. The statistical read favours the buyers, held for 2 days.
As held on the ledger · 2026-09-21
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 2 days
Price at the screen
$215.84
Valuation
38.47 trailing · 23.22 forward price to earnings
Values screen
PASS· score 88.2
Beta
0.81
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.60%
Below 33%
Interest-bearing debt is just 23.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
10.22%
Below 49%
Money owed to the company is 10.2% of assets, under the 49% limit.
Pass
Revenue purity
0.12%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Danaher clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-09-24. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades at roughly a 1% discount to our $217.25 fair value, narrow competitive moat, 5.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 0.7% margin of safety to the base estimate.
Third-party analyst targets: 23 covering, consensus Strong Buy. The average target sits +7% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Precision Health Tech with a Margin of Safety
Imagine the precision of a Swiss watch, but in healthcare diagnostics. That's Danaher Corporation, a company that designs and manufactures products and services that advance science and health, and right now, it's priced just a hair above our fair value of $217.27. Why it stands out is its commitment to precision health tech, with a forward P/E of 23.2x, which is in line with the market's expectations of its steady 6% revenue growth.
However, while its profit margins sit at a robust 16%, the return on equity of 8% and a narrow moat suggest Danaher has a modest competitive edge. The market is bullish, with 23 analysts giving it a strong buy consensus and a median target of $230, but it's important to remember that the valuation already seems to price in a lot of optimism. Risk here is on the table, especially considering the high analyst ratings can sometimes create a halo effect, overshadowing the potential downside.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DHR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Markup · changed$215.91+5.9%Entry 9
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248.
2026-07-21Markdown$203.83+0.0%Entry 8
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Markdown$203.83+0.0%Entry 7
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Markdown$203.83+10.6%Entry 6
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 10.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markdown$184.30+0.0%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17Markdown$184.30+0.0%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-16Markdown$184.30+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 8%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (23 analysts) rates it strong buy, with a mean price target of $248. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-03Markdown$184.30+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$184.30Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
